BAY-1797 (BAY1797) is a potent and selective P2X4 inhibitor/antagonist with IC50 of 211 nM (hP2X4).
BAY-1797 is suitable for in vivo studies in rodents.
BAY-1797 demonstrated anti-inflammatory and anti-nociceptive effects in a mouse complete Freund's adjuvant (CFA) inflammatory pain model.
BAY-1797 displays no or very weak activity on the other P2X ion channels (humanP2X1, P2X23, P2X3, P2X7, all IC50 >8.3 uM), does not inhibit hERG and Carbonic Anhydrase II, also is selective against a panel of off-targets, including GPCRs, ion channels, kinases, and transporters at 10 uM.
